Genitourinary Syndrome of MenopauseNCT06768073
Intravaginal Negative Pressure Medical Device for Treatment of Genitourinary Syndrome of Menopause (GSM)
A study of Genitourinary Syndrome of Menopause, run by AVeta Medical at 2 sites in 2 countries.
Trial summary
This pilot study aims to evaluate the safety and effectiveness of the VITA AV Clinical System over a period of up to three months after the last treatment, compared to a sham device. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Genitourinary Syndrome of Menopause
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 3 Mar 2025to 3 Nov 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Healthy postmenopausal subjects from 1 to 15 years since their last menstrual cycle.
- Willingness to refrain from using alternative therapies for treatment of symptoms of GSM, unless medically necessary, through the duration of this study.
- Moderate to severe dyspareunia associated with GSM. (i.e., ≥4 on the 11-point patient-reported numeric rated dyspareunia scale).
- Subjects who are sexually active (i.e. have had or have attempted to have sexual activity with vaginal penetration within approximately 1 month of screening visit).
- Subjects who anticipate engaging or attempting to engage in sexual activity (with vaginal penetration) at least twice a month during the trial.
- Vaginal Health Index (VHI) score of less than or equal to 15.
Show all 17Show fewer
- Vaginal pH >5.0.
- The subject is anatomically suitable to the intravaginal tip as determined by the Investigator.
- Normal Papanicolaou test within the past year (or should be done 2 weeks before the trial begins). Subject can ONLY participate on negative results.
- Vaginal canal free of any lesions other than symptoms of GSM as determined by the Investigator.
- Negative screening for chlamydia, gonorrhea, bacterial vaginosis, trichomonas and yeast.
- Willingness and ability to give voluntary written informed consent to participate in the study and comply with protocol requirements.
- Willingness to refrain from sexual intercourse for at least 48 hours before all visits and for at least 48 hours after all treatments.
- Willingness to stop using current vaginal lubricant, moisturizers or similar and only use the lubricant provided by the clinic.
- Willingness to stop using the clinic assigned lubricant for at least 48 hours before all scheduled visits post screening.
- Willingness to refrain from any pelvic floor therapy for the duration of the trial.
- Willingness to refrain from enrolling in another clinical trial for the duration of this study.
Who cannot join
- Subjects on Hormone Therapies (HT), systemic or local, or within 6 months of cessation of HT prior to inclusion in the study.
- Subjects with bleeding disorders.
- Subjects with any sexually transmitted disease.
- Subjects on prescribed anticoagulants such as antiplatelets and anticoagulants (Heparin, Warfarin, Clopidogrel, Apixaban, Rivaroxaban).
- Any active genital infections.
- Abnormal Papanicolaou test within the past year.
Show all 20Show fewer
- Positive pregnancy test or planned pregnancy during the study period.
- Complete procidentia or prolapse that in investigator opinion would be unsuitable for probe placement.
- Subjects with urogenital sinus (this is when urethral opening is combined with the vagina opening), otherwise the urethral opening will be traumatized potentially resulting in a urinary tract infection (UTI).
- Subjects with a compromised immune system.
- Subjects who have undergone pelvic irradiation treatment.
- Subjects who have undergone off-label procedures such as "vaginal rejuvenation" (e.g., laser or thermoablative techniques).
- Pelvic surgery within 6 months prior to the start of the study.
- Undiagnosed vaginal bleeding.
- Subjects with bleeding during screening examination due to friable vaginal mucosa and/or very thin epithelial layer, such that investigator determines the VITA AV treatment would be contraindicated.
- Subjects receiving chemotherapy or radiotherapy or subjects with any diagnosed gynecological cancers.
- History of breast cancer who have had chemotherapy within the last 5 years or are on aromatase inhibitors.
- Any general health or anatomical conditions, mental health or social situation which, in the opinion of the investigator, could represent an increased risk for the subject, or the ability of the subject to complete study requirements.
- Currently participating or considering participation in any other research of an investigational drug or device. Does not include observational studies.
- Subjects that have previously received this treatment as part of a clinical trial.
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
United States1 site
IMA Clinical Research,
Warren Township, New Jersey, 07059
Nancy Philips
Georgia1 site
Pineo Clinic (Pineo Medical Ecosystem)
Tbilisi, 0114
Zaza Sinauridze
About this study
Official title: Clinical Outcomes and Safety of an Intravaginal Negative Pressure Medical Device in the Treatment of Genitourinary Syndrome of Menopause (GSM): A Pilot Study
This pilot study aims to evaluate the safety and effectiveness of the VITA AV Clinical System over a period of up to three months after the last treatment, compared to a sham device. The study focuses on improving vaginal signs and symptoms of Genitourinary Syndrome of Menopause (GSM) in post-menopausal women who experience moderate to severe pain during intercourse (dyspareunia). Long-term follow-up visits will assess the ongoing effectiveness and durability of the treatment, while also collecting safety data.
Read the detailed description
There will be up to 6 in-person visits (screening visit, 4 treatment visits and 2 follow-up visits) for all subjects.
Screening After signing the informed consent form, subjects will be screened to ensure they meet the inclusion and exclusion criteria before initiating treatment.
Screening includes collecting information from the patient history (medical history, demographics and medications) as well as conducting the following clinical assessments:
- Dilator suitability.
- Papanicolaou Test (current within last year or repeated within 2 weeks of initial treatment).
- Sexually transmitted infections screening test (gonorrhea, chlamydia, bacterial vaginosis, trichomonas and yeast)
- Pregnancy Test
- Vaginal Health Index (VHI) Score.
- Vaginal pH.
- Clinical examination to confirm that the vaginal canal is free of any lesions other than symptoms of GSM.
- Self-assessment of symptoms related to GSM and confirmation of moderate to severe dyspareunia.
All screening information necessary to evaluate whether the subject meets the inclusion/exclusion criteria should be available and reviewed prior to treatment. Subjects who do not meet the eligibility criteria upon screening will be considered screening failures. Screening failures will not be followed further except in case of adverse events occurring at the screening visit. In this case, subjects will be monitored until the adverse event(s) are resolved.
The eligible subjects will be randomized and introduced to the treatment at the first treatment visit.
Treatment Visits
The following are completed prior to treatment:
- Pre-Treatment Assessments
- Urinary Tract Infection Test.
- Vaginal pH.
- Vaginal moisture (modified Schirmer Test).
- Vaginal Maturation Index (VMI) Score.
- Clinical Examination - Immediately prior to each treatment, a visual examination of the vulvo-vaginal area is carried out. The appearance of the vaginal mucosa before each treatment will be assessed (by the same investigator for each subject) taking parameters of Vaginal Mucosa Assessment (VMA) into account.
- Vaginal Health Index (VHI) Score.
- Imaging of Vaginal Wall - An image of the mucosa will be taken after the clinical examination and prior to each treatment.
- Self-assessment of symptoms related to GSM and confirmation of moderate to severe dyspareunia.
- Female Sexual Function Index (FSFI) questionnaire.
- Randomization
Before initiating treatment, subjects continuing to meet eligibility criteria will be randomized to one of following two arms:
- VITA AV Clinical System (active treatment).
- Sham device.
Each active treatment is delivered at a negative pressure of 460 mmHg for 5 minutes. After the treatment, the clinician will re-assess the vaginal mucosa to review the induced micro-trauma, if any. This appears as visible dome shaped effects on the vaginal mucosa corresponding to the apertures in the intravaginal tip. They may appear red indicating induced petechiae, which is the desired response. Images will be taken after each treatment to record the treatment effect at site # 2.
After the initial treatment, each subject returns for an additional 3 treatments performed at 4-week intervals (+/-4 days) for a total of four treatments.
In addition, the following are assessed, as part of the clinical examination, prior to performing subsequent treatments to ensure that the vaginal canal is free from:
- bleeding,
- inflammation,
- the desired microtrauma effects of any previous treatment.
- other abnormal effects.
Follow-Up Visits:
Will occur at 1-, 3- post the last treatment will take place for all subjects. Will occur at 6-, 9- and 12-months post the last treatment will take place for subjects in the Active treatment only.
Note: The 9-month follow-up visit will be conducted via phone call.
- Conditions
- Genitourinary Syndrome of Menopause
- Being tested
- Sham (No Treatment)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sham (No Treatment)Device
The Sham device is identified to the Active device with the exception that it has a black connector component, part number 10531-02, to block the vacuum from reaching the vaginal tissue with vacuum pump activation. In this manner, the control procedure has been designed to mimic the active therapy to the extent practicable allowing for subject blinding.
| Study group | Role | What they receive |
|---|---|---|
| Active Treatment | Experimental | The VITA AV Clinical System (consisting of the VITA AV Probe Kit and the Medela Pump), has a white connector component, part number 10531-01, to allow the vacuum to be delivered to the vaginal tissue when then vacuum pump is activated. Receives: Device: Sham (No Treatment) |
| Sham Treatment | Sham comparator | The VITA AV Clinical System (consisting of the VITA AV Probe Kit and the Medela Pump), has a black connector component, part number 10531-02, to block and prevent the vacuum from being delivered to the vaginal tissue when then vacuum pump is activated. Receives: Device: Sham (No Treatment) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety Evaluation of the VITA AV Clinical System compared to a sham device from baseline to 3-months post the last treatment.
Safety will be assessed by monitoring all adverse events, with particular attention to serious adverse events (SAEs) related to the device or procedure.
Measured: Baseline to 3-months post the last treatment.
Percentage of Vaginal Superficial Cells to evaluate the performance of the VITA AV Clinical System compared to a sham device from baseline to 3-months post the last treatment.
Quantified using cytological analysis to determine the percentage of superficial cells. Changes will be assessed from baseline up to 3 months following the last treatment. To minimize bias, the clinical exams conducted at the 1-month and 3-month post-treatment visits will be performed by a physician blinded to randomization assignment.
Measured: Baseline to 3-months post the last treatment.
Vaginal Moisture Levels to evaluate the performance of the VITA AV Clinical System compared to a sham device from baseline to 3-months post the last treatment.
Measured using the modified Schirmer Test to assess changes in vaginal hydration levels. Changes will be assessed from baseline up to 3 months following the last treatment. To minimize bias, the clinical exams conducted at the 1-month and 3-month post-treatment visits will be performed by a physician blinded to randomization assignment.
Measured: Baseline to 3-months post the last treatment.
Vaginal pH Levels to evaluate the performance of the VITA AV Clinical System compared to a sham device from baseline to 3-months post the last treatment.
Measured by inserting a cotton swab vaginally, and applying it to the vaginal pH strip to determine changes in vaginal acidity. Changes will be assessed from baseline up to 3 months following the last treatment. To minimize bias, the clinical exams conducted at the 1-month and 3-month post-treatment visits will be performed by a physician blinded to randomization assignment.
Measured: Baseline to 3-months post the last treatment.
Secondary outcomes (6)
Vaginal Health Index (VHI) changes from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Evaluated using the Vaginal Health Index, which includes assessments of vaginal elasticity, fluid volume, pH, epithelial integrity, and moisture. Changes will be assessed from baseline, at each visit during the treatment phase and up to the 3-month follow-up. To minimize bias, the clinical exams conducted at the 1-month and 3-month post-treatment visits will be performed by a physician blinded to randomization assignment.
Measured: Baseline to 3-months post the last treatment.
Vaginal Maturation Index (VMI) changes from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Assessed using cytological analysis to determine the proportion of parabasal, intermediate, and superficial cells. Changes will be assessed from baseline, at each visit during the treatment phase and up to the 3-month follow-up. To minimize bias, the clinical exams conducted at the 1-month and 3-month post-treatment visits will be performed by a physician blinded to randomization assignment.
Measured: Baseline to 3-months post the last treatment.
Vaginal Mucosa Assessment (VMA) changes from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Evaluated through clinical examination of the vaginal mucosa, including assessments of atrophy, dryness, and inflammation. Changes will be assessed from baseline, at each visit during the treatment phase and up to the 3-month follow-up. To minimize bias, the clinical exams conducted at the 1-month and 3-month post-treatment visits will be performed by a physician blinded to randomization assignment.
Measured: Baseline to 3-months post the last treatment.
Severity of GSM Symptoms changes from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Assessed using a validated symptom severity scale, an 11-point a Visual Analogue Scale (VAS) to evaluate changes in the severity of GSM symptoms.
Scale breakdown as reported by the subject is as follows: 0 = None (symptom is not present); 1 - 3 = Mild; 4 - 6 = Moderate; and 7 - 10 = Severe.
Changes will be assessed from baseline, at each visit during the treatment phase and up to the 3-month follow-up.
Measured: Baseline to 3-months post the last treatment.
Durability of Benefit from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Assessed using a subject-completed questionnaire to determine the perceived benefit from the treatment and the duration of its effects. Changes will be assessed from baseline, at each visit during the treatment phase and up to the 3-month follow-up.
Measured: Baseline to 3-months post the last treatment.
Female Sexual Function Index (FSFI) from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Assessed using the FSFI to evaluate changes in sexual function, including domains such as desire, arousal, lubrication, orgasm, satisfaction, and pain. Changes will be assessed from baseline, at each visit during the treatment phase and up to the 3-month follow-up.
Measured: Baseline to 3-months post the last treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2025
- Study start3 Mar 2025 (estimated)
- Primary completion3 Nov 2025 (estimated)
- Study completion3 Nov 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Genitourinary Syndrome of MenopauseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AVeta Medical
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Nancy Philips, Principal investigator, IMA Clinical Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06768073
- Sponsor's protocol ID
- 10510
- Status last verified
- Jan 2025
- First submitted
- 13 Dec 2024
- Last updated
- 10 Jan 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 10 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Outcomes and Safety of an Intravaginal Negative Pressure Medical Device in the Treatment of Genitourinary Syndrome of Menopause (GSM): A Pilot Study
- ClinicalTrials.gov ID
- NCT06768073
- Acronym / sponsor ID
- 10510
- Conditions
- Genitourinary Syndrome of Menopause
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- AVeta MedicalUniversity, hospital or other
- Study start
- 3 Mar 2025 (estimated)
- Primary completion
- 3 Nov 2025 (estimated)
- Study completion
- 3 Nov 2025 (estimated)
- First posted
- 10 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pilot study aims to evaluate the safety and effectiveness of the VITA AV Clinical System over a period of up to three months after the last treatment, compared to a sham device. The study focuses on improving vaginal signs and symptoms of Genitourinary Syndrome of Menopause (GSM) in post-menopausal women who experience moderate to severe pain during intercourse (dyspareunia). Long-term follow-up visits will assess the ongoing effectiveness and durability of the treatment, while also collecting safety data.
Detailed description
There will be up to 6 in-person visits (screening visit, 4 treatment visits and 2 follow-up visits) for all subjects.
Screening After signing the informed consent form, subjects will be screened to ensure they meet the inclusion and exclusion criteria before initiating treatment.
Screening includes collecting information from the patient history (medical history, demographics and medications) as well as conducting the following clinical assessments:
- Dilator suitability.
- Papanicolaou Test (current within last year or repeated within 2 weeks of initial treatment).
- Sexually transmitted infections screening test (gonorrhea, chlamydia, bacterial vaginosis, trichomonas and yeast)
- Pregnancy Test
- Vaginal Health Index (VHI) Score.
- Vaginal pH.
- Clinical examination to confirm that the vaginal canal is free of any lesions other than symptoms of GSM.
- Self-assessment of symptoms related to GSM and confirmation of moderate to severe dyspareunia.
All screening information necessary to evaluate whether the subject meets the inclusion/exclusion criteria should be available and reviewed prior to treatment. Subjects who do not meet the eligibility criteria upon screening will be considered screening failures. Screening failures will not be followed further except in case of adverse events occurring at the screening visit. In this case, subjects will be monitored until the adverse event(s) are resolved.
The eligible subjects will be randomized and introduced to the treatment at the first treatment visit.
Treatment Visits
The following are completed prior to treatment:
- Pre-Treatment Assessments
- Urinary Tract Infection Test.
- Vaginal pH.
- Vaginal moisture (modified Schirmer Test).
- Vaginal Maturation Index (VMI) Score.
- Clinical Examination - Immediately prior to each treatment, a visual examination of the vulvo-vaginal area is carried out. The appearance of the vaginal mucosa before each treatment will be assessed (by the same investigator for each subject) taking parameters of Vaginal Mucosa Assessment (VMA) into account.
- Vaginal Health Index (VHI) Score.
- Imaging of Vaginal Wall - An image of the mucosa will be taken after the clinical examination and prior to each treatment.
- Self-assessment of symptoms related to GSM and confirmation of moderate to severe dyspareunia.
- Female Sexual Function Index (FSFI) questionnaire.
- Randomization
Before initiating treatment, subjects continuing to meet eligibility criteria will be randomized to one of following two arms:
- VITA AV Clinical System (active treatment).
- Sham device.
Each active treatment is delivered at a negative pressure of 460 mmHg for 5 minutes. After the treatment, the clinician will re-assess the vaginal mucosa to review the induced micro-trauma, if any. This appears as visible dome shaped effects on the vaginal mucosa corresponding to the apertures in the intravaginal tip. They may appear red indicating induced petechiae, which is the desired response. Images will be taken after each treatment to record the treatment effect at site # 2.
After the initial treatment, each subject returns for an additional 3 treatments performed at 4-week intervals (+/-4 days) for a total of four treatments.
In addition, the following are assessed, as part of the clinical examination, prior to performing subsequent treatments to ensure that the vaginal canal is free from:
- bleeding,
- inflammation,
- the desired microtrauma effects of any previous treatment.
- other abnormal effects.
Follow-Up Visits:
Will occur at 1-, 3- post the last treatment will take place for all subjects. Will occur at 6-, 9- and 12-months post the last treatment will take place for subjects in the Active treatment only.
Note: The 9-month follow-up visit will be conducted via phone call.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active Treatment | Experimental | Device: Sham (No Treatment)The VITA AV Clinical System (consisting of the VITA AV Probe Kit and the Medela Pump), has a white connector component, part number 10531-01, to allow the vacuum to be delivered to the vaginal tissue when then vacuum pump is activated. |
| Sham Treatment | Sham comparator | Device: Sham (No Treatment)The VITA AV Clinical System (consisting of the VITA AV Probe Kit and the Medela Pump), has a black connector component, part number 10531-02, to block and prevent the vacuum from being delivered to the vaginal tissue when then vacuum pump is activated. |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (17 listed)
- Healthy postmenopausal subjects from 1 to 15 years since their last menstrual cycle.
- Willingness to refrain from using alternative therapies for treatment of symptoms of GSM, unless medically necessary, through the duration of this study.
- Moderate to severe dyspareunia associated with GSM. (i.e., ≥4 on the 11-point patient-reported numeric rated dyspareunia scale).
- Subjects who are sexually active (i.e. have had or have attempted to have sexual activity with vaginal penetration within approximately 1 month of screening visit).
- Subjects who anticipate engaging or attempting to engage in sexual activity (with vaginal penetration) at least twice a month during the trial.
Key exclusion criteria (20 listed)
- Subjects on Hormone Therapies (HT), systemic or local, or within 6 months of cessation of HT prior to inclusion in the study.
- Subjects with bleeding disorders.
- Subjects with any sexually transmitted disease.
- Subjects on prescribed anticoagulants such as antiplatelets and anticoagulants (Heparin, Warfarin, Clopidogrel, Apixaban, Rivaroxaban).
- Any active genital infections.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sham (No Treatment)The Sham device is identified to the Active device with the exception that it has a black connector component, part number 10531-02, to block the vacuum from reaching the vaginal tissue with vacuum pump activation. In this manner, the control procedure has been designed to mimic the active therapy to the extent practicable allowing for subject blinding. | Device | Active Treatment, Sham Treatment |
Primary outcome
Safety Evaluation of the VITA AV Clinical System compared to a sham device from baseline to 3-months post the last treatment.
Time frame: Baseline to 3-months post the last treatment.
Safety will be assessed by monitoring all adverse events, with particular attention to serious adverse events (SAEs) related to the device or procedure.
Percentage of Vaginal Superficial Cells to evaluate the performance of the VITA AV Clinical System compared to a sham device from baseline to 3-months post the last treatment.
Time frame: Baseline to 3-months post the last treatment.
Quantified using cytological analysis to determine the percentage of superficial cells. Changes will be assessed from baseline up to 3 months following the last treatment. To minimize bias, the clinical exams conducted at the 1-month and 3-month post-treatment visits will be performed by a physician blinded to randomization assignment.
Vaginal Moisture Levels to evaluate the performance of the VITA AV Clinical System compared to a sham device from baseline to 3-months post the last treatment.
Time frame: Baseline to 3-months post the last treatment.
Measured using the modified Schirmer Test to assess changes in vaginal hydration levels. Changes will be assessed from baseline up to 3 months following the last treatment. To minimize bias, the clinical exams conducted at the 1-month and 3-month post-treatment visits will be performed by a physician blinded to randomization assignment.
Vaginal pH Levels to evaluate the performance of the VITA AV Clinical System compared to a sham device from baseline to 3-months post the last treatment.
Time frame: Baseline to 3-months post the last treatment.
Measured by inserting a cotton swab vaginally, and applying it to the vaginal pH strip to determine changes in vaginal acidity. Changes will be assessed from baseline up to 3 months following the last treatment. To minimize bias, the clinical exams conducted at the 1-month and 3-month post-treatment visits will be performed by a physician blinded to randomization assignment.
6 secondary outcomes
Vaginal Health Index (VHI) changes from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Time frame: Baseline to 3-months post the last treatment.
Vaginal Maturation Index (VMI) changes from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Time frame: Baseline to 3-months post the last treatment.
Vaginal Mucosa Assessment (VMA) changes from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Time frame: Baseline to 3-months post the last treatment.
Severity of GSM Symptoms changes from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Time frame: Baseline to 3-months post the last treatment.
Durability of Benefit from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Time frame: Baseline to 3-months post the last treatment.
Female Sexual Function Index (FSFI) from baseline to each visit (treatment phase and up to the 3-month follow-up) for treatment with the VITA AV Clinical System compared to a sham device.
Time frame: Baseline to 3-months post the last treatment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jan 2025.
Related trials for Genitourinary Syndrome of Menopause
Active, not recruiting
Reexamining Her Cardiovascular Risk - Ottawa WomeN's Longitudinal Cohort Study
Cardiovascular Diseases
RecruitingObservational study
Predictors of Religious Orientation Attitudes in Menopausal Women
Menopause, Menopausal Syndrome
Not yet recruitingObservational study
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Not yet recruitingPhase 4
Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV
Menopausal Complaints, Vaginal Atrophy
Not yet recruiting
Photobiomodulation for Vaginal Dysfunctions: Home-Based vs Outpatient Treatment
Genitourinary Syndrome of Menopause (GSM), Bacterial Vaginosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nancy Philips principal investigator
IMA Clinical Research
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Genitourinary Syndrome of Menopause, run by AVeta Medical at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Georgia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Orla O'Loughlin (+353 87 248 3582, orla@avetamedical.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety Evaluation of the VITA AV Clinical System compared to a sham device from baseline to 3-months post the last treatment. (time frame: Baseline to 3-months post the last treatment.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2025.